Selective Thyroid Hormone Receptor Beta Agonist for Cholesterol Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Previous thyroid hormone receptor agonists have shown deleterious cardiovascular side effects and significant effects on the thyroid hormone axis while attempting to lower cholesterol levels, lacking a favorable safety profile.
Innovation Solution
A compound, referred to as Compound I, selectively activates thyroid hormone receptor β with minimal cardiovascular effects, rapidly clearing from the system and maintaining thyroid hormone levels, thus offering a safer therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If thyroid hormone receptor agonists are used to lower cholesterol levels, then cholesterol levels are reduced, but cardiovascular side effects occur
Solution Approach 1:
The patent applies local quality by designing a compound that selectively activates thyroid hormone receptor β (TRβ) while avoiding activation of TRα and other receptors. This selective activation at the molecular level achieves cholesterol reduction without the cardiovascular side effects associated with non-selective agonists, as TRβ is predominantly expressed in the liver and pituitary rather than the heart
2Quantity of substance
If thyroid hormone receptor agonists are used to lower cholesterol levels, then cholesterol levels are reduced, but effects on the thyroid hormone axis occur
Solution Approach 1:
The compound exhibits local quality through selective TRβ activation, which regulates cholesterol metabolism and TSH production without disrupting the overall thyroid hormone axis. The selective mechanism ensures that only specific functions mediated by TRβ are modulated while preserving normal thyroid hormone physiology
3Quantity of substance
If non-selective thyroid hormone receptor agonists are used, then cholesterol levels are reduced, but therapeutic index is reduced due to adverse effects
Solution Approach 1:
The patent achieves an improved therapeutic index through local quality selectivity - the compound specifically targets TRβ for cholesterol reduction while avoiding off-target effects on TRα and other receptors. This molecular-level selectivity creates a wider therapeutic window by separating the desired cholesterol-lowering effect from the adverse cardiovascular and thyroid axis effects
Solution Approach 2:
The invention applies parameter changes by modifying the chemical structure of thyroid hormone analogs to achieve selective TRβ binding. The structural modifications alter the pharmacological parameters of the compound, enabling selective receptor activation that improves the therapeutic index while maintaining cholesterol-lowering efficacy
Data Source
AI summary
A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.